<u>s</u>.B. NO. 967

JAN 2 6 2009

A BILL FOR AN ACT

RELATING TO CONTROLLED SUBSTANCES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. Section 329-16, Hawaii Revised Statutes, is					
2	amended by amending subsection (b) to read as follows:					
3	"(b) Any of the following substances, except those					
4	narcotic drugs listed in other schedules, whether produced					
5	directly or indirectly by extraction from substances of					
6	vegetable origin, or independently by means of chemical					
7	synthesis, or by combination of extraction and chemical					
8	synthesis:					
9	(1) Opium and opiate, and any salt, compound, derivative,					
10	or preparation of opium or opiate, including the					
11	following:					
12	(A) Raw opium;					
13	(B) Opium extracts;					
14	(C) Opium fluid;					
15	(D) Powdered opium;					
16	(E) Granulated opium;					
17	(F) Codeine;					

<u>S</u>.B. NO. <u>967</u>

1		(G) Ethylmorphine;			
2		(H) Etorphine hydrochloride;			
3		(I) Hydrocodone;			
4		(J) Hydromorphone;			
5		(K) Metopon;			
6		(L) Morphine;			
7		(M) Oxycodone;			
8		(N) Oxymorphone; [and]			
9		(0) Thebaine;			
10		(P) Dihydroetorphine;			
11		(Q) Oripavine; and			
12)	(R) Tincher of opium.			
13	(2)	Any salt, compound, isomer, derivative, or preparation			
14		thereof which is chemically equivalent or identical			
15		with any of the substances referred to in paragraph			
16		(1), but not including the isoquinoline alkaloids of			
17		opium;			
18) (3)	Opium poppy and poppy straw;			
19	(4)	Coca leaves and any salt, compound, derivative, or			
20		preparation of coca leaves, and any salt, compound,			
21		derivative, or preparation thereof which is chemically			
22		equivalent or identical with any of these substances,			
	9 ⁴ .				

<u>S.B. NO.</u> 967

1		but not including decocanized coca leaves or
2		extractions which do not contain cocaine or ecgonine;
3		cocaine or any salt or isomer thereof; and
4	(5)	Concentrate of poppy straw (the crude extract of poppy
5		straw in either liquid, solid, or powder form that
6		contains the phenanthrene alkaloids of the opium
7		poppy)."
8	SECT	ION 2. Section 329-16, Hawaii Revised Statutes, is
9	amended b	y amending subsection (e) to read as follows:
10	" (e)	Stimulants. Any material, compound, mixture, or
11	preparati	on which contains any quantity of the following
12	substance	s having a danger or probable danger associated with a
13	stimulant	effect on the central nervous system:
14	(1)	Amphetamine, its salts, optical isomers, and salts of
15		its optical isomers;
16	(2)	Any substance which contains any quantity of
17		methamphetamine, including its salts, isomers, and
18		salts of isomers;
19	(3)	Phenmetrazine and its salts; [and]
20	(4)	Methylphenidate[-]; and
21	(5)	Lisdexamfetamine, its salts, isomers, and salts of its
22		isomers."

Page 4

<u>s</u>.B. NO. <u>967</u>

1	SECI	YION 3. Section 329-18, Hawaii Revised Statutes, is				
2	amended by amending subsection (g) to read as follows:					
3	"(g) Any anabolic steroid. The term "anabolic steroid"					
4	means any	drug or hormonal substance chemically and				
5	pharmacol	ogically related to testosterone (other than estrogens,				
6	progestin	s, and corticosteroids) that promotes muscle growth, and				
7	includes:					
8	(1)	Boldenone;				
9	(2)	Clostebol (4-Chlorotestosterone);				
10	(3)	Dehydrochlormethyltestosterone;				
11	(4)	Dihydrotestosterone (4-dihydrotestosterone);				
12	(5)	Drostanolone;				
13	(6)	Ethylestrenol;				
14	(7)	Fluoxymesterone;				
15	(8)	Formebolone (Formyldienolone);				
16	(9)	Mesterolone;				
17	(10)	Methandranone;				
18	(11)	Methandriol;				
19	(12)	Methandrostenolone (Methandienone);				
20	(13)	Methenolone;				
21	(14)	Methyltestosterone;				
22	(15)	Mibolerone;				

<u>S.B. NO.</u> 967

1	(16)	Nandrolone;			
2	(17)	Norethandrolone;			
3	(18)	Oxandrolone;			
4	(19)	Oxymesterone;			
5	(20)	Oxymetholone;			
6	(21)	Stanolone (Dihydrotestosterone);			
7	(22)	Stanozolol;			
8	(23)	Testolactone;			
9	(24)	Testosterone;			
10	(25)	Trenbolone; [and]			
11	(26)	3[beta], 17-dihydroxy-5a-androstane;			
12	(27)	3[alpha], 17[beta]-dihydroxy-5a-androstane;			
13	(28)	5[alpha]-androstan-3, 17-dione;			
14	(29)	1-androstenediol (3[beta], 17[beta]-dihydroxy-			
15		5[alpha]-androst-1-ene);			
16	(30)	1-androstenediol (3[alpha], 17[beta]-dihydroxy-			
17		5[alpha]-androst-1-ene);			
18	(31)	4-androstenediol (3[beta], 17[beta]-dihydroxy-			
19		androst-4-ene);			
20	(32)	5-androstenediol (3[beta], 17[beta]-dihydroxy-			
21		androst-5-ene);			

<u>S.B. NO.</u> 967

1	(33)	1-androstenedione ([5[alpha]]-androst-1-en-3, 17-
2		dione);
3	(34)	4-androstenedione (androst-4-en-3, 17-dione);
··· 4	(35)	5-androstenedione (androst-5-en-3, 17-dione);
5	(36)	Bolasterone (7[alpha], 17[alpha]-dimethyl-
6		17[beta]-hydroxyandrost-4-en-3-one);
7	(37)	Calusterone (7[beta], 17[alpha]-dimethyl-17[beta]-
8		hydroxyandrost-4-en-3-one);
9	(38)	[Delta]1-dihydrotestosterone (a.k.a. `1-
10		testosterone') (17[beta]-hydroxy-5[alpha]-androst-
11		1-en-3-one);
12	(39)	Furazabol (17[alpha]-methyl-17[beta]-
12 13	(39)	<pre>Furazabol (17[alpha]-methyl-17[beta]- hydroxyandrostano[2,3-c]-furazan);</pre>
	(39)	
13		hydroxyandrostano[2,3-c]-furazan);
13 14	(40)	hydroxyandrostano[2,3-c]-furazan); 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;
13 14 15	(40)	hydroxyandrostano[2,3-c]-furazan); 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; 4-hydroxytestosterone (4,17[beta]-dihydroxy-
13 14 15 16	<u>(40)</u> (41)	<pre>hydroxyandrostano[2,3-c]-furazan); 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; 4-hydroxytestosterone (4,17[beta]-dihydroxy- androst-4-en-3-one);</pre>
13 14 15 16 17	<u>(40)</u> (41)	<pre>hydroxyandrostano[2,3-c]-furazan); 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; 4-hydroxytestosterone (4,17[beta]-dihydroxy- androst-4-en-3-one); 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy-</pre>
13 14 15 16 17 18	<u>(40)</u> (41) (42)	<pre>hydroxyandrostano[2,3-c]-furazan); 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; 4-hydroxytestosterone (4,17[beta]-dihydroxy- androst-4-en-3-one); 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy- estr-4-en-3-one);</pre>
13 14 15 16 17 18 19	<u>(40)</u> (41) (42)	<pre>hydroxyandrostano[2,3-c]-furazan); 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; 4-hydroxytestosterone (4,17[beta]-dihydroxy- androst-4-en-3-one); 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy- estr-4-en-3-one); Mesterolone (1[alpha]methyl-17[beta]-hydroxy-</pre>

<u>s</u>.B. NO. **967**

1	(45)	Methandriol (17[alpha]-methyl-3[beta],17[beta]-
2		dihydroxyandrost-5-ene);
3	(46)	Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-
4		androst-1-en-3-one);
5	(47)	17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-
6		androstane;
7	(48)	17[alpha]-methyl-3[alpha], 17[beta]-dihydroxy-5a-
8		androstane;
9	(49)	17[alpha]-methyl-3[beta], 17[beta]-dihydroxyandrost-4-
10	· (ene;
11	(50)	17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
12		<pre>methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);</pre>
13	(51)	Methyldienolone (17[alpha]-methyl-17[beta]-
14		hydroxyestra-4,9(10)-dien-3-one);
15	(52)	Methyltrienolone (17[alpha]-methyl-17[beta]-
16		hydroxyestra-4, 9-11-trien-3-one);
17	(53)	17[alpha]-methyl-[Delta]1-dihydrotestosterone
18		(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-
19		1-en-3-one) (a.k.a. '17-[alpha]-methyl-1-
20		testosterone');
21	(54)	19-nor-4-androstenediol (3[beta], 17[beta]-
22		dihydroxyestr-4-ene);

Page 7

<u>s</u>.b. NO. <u>967</u>


1	(55)	19-nor-4-androstenediol (3[alpha], 17[beta]-
2	·	dihydroxyestr-4-ene);
3	(56)	19-nor-5-androstenediol (3[beta], 17[beta]-
4		dihydroxyestr-5-ene);
5	(57)	19-nor-5-androstenediol (3[alpha], 17[beta]-
6		dihydroxyestr-5-ene);
7	(58)	19-nor-4-androstenedione (estr-4-en-3, 17-dione);
8	(59)	19-nor-5-androstenedione (estr-5-en-3, 17-dione;
9	(60)	Norbolethone (13[beta], 17[alpha]-diethyl-
10		17[beta]-hydroxygon-4-en-3-one);
11	(61)	Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-
12		<u>3-one);</u>
13	(62)	Normethandrolone (17[alpha]-methyl-17[beta]-
14		hydroxyestr-4-en-3-one);
15	(63)	Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-
16		androst-1-en-3-one);
17	(64)	Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-
18		17[beta]-hydroxygon-4,9,11-trien-3-one); and
19	[(26)]	(65) Any salt, ester, or isomer of a drug or
20		substance described or listed in this subsection,
21		if that salt, ester, or isomer promotes muscle
22		growth, except the term "anabolic steroid" does not

<u>S</u>.B. NO. <u>967</u>

1 include an anabolic steroid which is expressly intended for administration through implants to 2 cattle or other nonhuman species and which has been 3 approved by the Secretary of Health and Human 4 Services for nonhuman administration. If any 5 person prescribes, dispenses, or distributes an 6 anabolic steroid intended for administration to 7 8 nonhuman species for human use, the person shall be considered to have prescribed, dispensed, or 9 distributed an anabolic steroid within the meaning 10 of this paragraph." 11

12 SECTION 4. Section 329-33, Hawaii Revised Statutes, is13 amended by amending subsection (a) to read as follows:

The department of public safety shall register an "(a) 14 applicant to manufacture, dispense, prescribe, or distribute 15 16 controlled substances included in sections 329-14, 329-16, 329-18, 329-20, and 329-22 unless it determines that the 17 issuance of that registration would be inconsistent with the 18 public interest. In determining the public interest, the 19 20 department of public safety shall consider the following factors: 21



(1)	Maintenance of effective controls against
	diversion of controlled substances into other
	than legitimate medical, scientific, or
	industrial channels;
(2)	Compliance with applicable state and local law;
(3)	Any convictions of the applicant under any
	federal and state laws relating to any controlled
	substance;
(4)	Past experience in the manufacture or
	distribution of controlled substances, and the
	existence in the applicant's establishment of
	effective controls against diversion;
(5)	Furnishing by the applicant of false or
	fraudulent material in any application filed
	under this chapter;
(6)	Suspension [or], revocation, or surrender of the
	applicant's federal registration to manufacture,
	distribute, prescribe, or dispense controlled
	substances as authorized by federal law; and
(7)	Any other factor relevant to and consistent with
	the public health and safety."
	 (2) (3) (4) (5) (6)

Page 11



1	SECT	ION 5. Section 329-34, Hawaii Revised Statutes, is
2	amended b	y amending subsection (a) to read as follows:
3	"(a)	A registration under section 329-33 to manufacture,
4	distribut	e, or dispense a controlled substance may be suspended
5	or revoke	d by the department of public safety upon a finding
6	that the	registrant:
7	(1)	Has furnished false or fraudulent material information
8		in any application filed under this chapter;
9	(2)	Has been convicted of a felony or has been granted a
10		motion for the deferral of acceptance of a guilty plea
11	·	or a nolo contendere plea to a felony, pursuant to
12		chapter 853 and under any state or federal law
13		relating to any controlled substance;
14	(3)	Has had the registrant's federal registration
15		suspended or revoked to manufacture, distribute,
16		prescribe, or dispense controlled substances; [or]
17	(4)	Has been requested to surrender the registrant's
18		federal registration to manufacture, distribute,
19		prescribe, or dispense controlled substances by the
20		Drug Enforcement Administration; or

<u>S.B. NO. 967</u>

1	$\left[\frac{4}{4}\right]$ (5) Has had the registrant's state license to				
2	practice the registrant's profession suspended or				
3	revoked by the applicable governing state board."				
4	SECTION 6. Section 329-38, Hawaii Revised Statutes, is				
5	amended by amending subsection (c) to read as follows:				
6	"(c) The transfer of original prescription information for				
7	a controlled substance listed in schedule III, IV, or V for the				
8	purpose of [refill] dispensing is permissible between pharmacies				
9	on a one time basis[, subject to the following requirements:]				
10	only. However, pharmacies electronically sharing a real-time,				
11	online database may transfer up to the maximum refills permitted				
12	by law and the prescriber's authorization. Transfers are				
13	subject to the following requirements:				
14	(1) The transfer shall be communicated directly between				
15	two licensed pharmacists, and the transferring				
16	pharmacist shall:				
17	(A) Write or otherwise place the word "VOID" on the				
18	face of the invalidated prescription;				
19	(B) Record on the reverse of the invalidated				
20	prescription the name, address, and DEA				
21	registration number of the pharmacy to which it				

<u>s</u>.b. NO. <u>967</u>

1		was	transferred and the name of the pharmacist
2		rece	iving the prescription information; and
3		(C) Reco	rd the date of the transfer and the name of
4		the	pharmacist transferring the information;
5	(2)	The pharm	acist receiving the transferred prescription
6		informati	on shall[+] reduce to writing the following:
7		(A) Writ	e or otherwise place the word "transfer" on
8		the	face of the transferred prescription;
9		(B) Reco	rd all information required to be on a
10		pres	cription, including:
11		(i)	The date of issuance of original
12			prescription;
13		(ii)	The original number of refills authorized on
14			original prescription;
15		(iii)	The date of original dispensing;
16		(iv)	The number of valid refills remaining and
17			[date of last refill;] dates and locations
18			of previous refills;
19		(v)	The pharmacy's name, address, DEA
20			registration number, and original
21			prescription number from which the

<u>s</u>.B. NO. <u>9</u>(4)

1	prescription information was transferred;	
2	[and]	
3	(vi) The name of transferor pharmacist; and	
4	(vii) The pharmacy's name, address, and DEA	
5	registration number, along with the	
6	prescription number from which the	
7	prescription was originally filled.	
8	(3) Both the original and transferred prescription shall	
9	be maintained for a period of five years from the dat	е
10	of last refill;	
11	[(4) The procedure allowing the transfer of prescription	
12	information for refill purposes is permissible only	
13	between pharmacies located on the same island in this	
14	State;] and	
15	[(5)] <u>(4)</u> Any pharmacy electronically accessing a	
16	prescription record shall satisfy all information	
17	requirements of a manual mode prescription transferal	•
18	Failure to comply with this subsection shall void the	
19	authority of the pharmacy to transfer prescriptions or receive	a
20	transferred prescription to or from another pharmacy."	
21	SECTION 7. Section 329-41, Hawaii Revised Statutes, is	
22	amended by amending subsection (a) to read as follows:	

<u>s</u>.B. NO. <u>967</u>

1 "(a) It is unlawful for any person:

(1) Who is subject to part III to distribute, administer, 2 3 prescribe, or dispense a controlled substance in violation of section 329-38 or rules authorized under 4 section 329-31; however, a licensed manufacturer or 5 wholesaler may sell or dispense a controlled substance 6 7 to a master of a transpacific ship or a person in charge of a transpacific aircraft upon which no 8 9 physician is regularly employed, for the actual medical needs of persons on board such ship or 10 aircraft when not in port; provided schedule I or II 11 controlled substances shall be sold to the master of 12 such ship or person in charge of such aircraft only in 13 accordance with the provisions set forth in 21 Code of 14 Federal Regulations, Sections 1301, 1305, and 1307, 15 adopted pursuant to Title 21, United States Code, 16 Section 821; 17

18 (2) Who is a registrant to manufacture a controlled
19 substance not authorized by the registrant's
20 registration or to distribute or dispense a controlled
21 substance not authorized by the registrant's

<u>s</u>.b. NO. <u>967</u>

1		registration to another registrant or another
2		authorized person;
3	(3)	To refuse or fail to make available, keep, or furnish
4		any record, notification, order form, prescription,
5		statement, invoice, or information in patient charts
6		relating to the administration, dispensing, or
7		prescribing of controlled substances;
8	(4)	To refuse any lawful entry into any premises for any
9		inspection authorized by this chapter;
10	(5)	Knowingly to keep or maintain any store, shop,
11		warehouse, dwelling, building, vehicle, boat,
12		aircraft, or other structure or place for the purpose
13		of using these substances or which is used for keeping
14		or selling them in violation of this chapter or
15		chapter 712, part IV;
16	(6)	Who is a practitioner or pharmacist to dispense a
17		controlled substance to any individual not known to
18		the practitioner or pharmacist, without first
19		obtaining proper identification and documenting[, by
20		signature on a log book kept by the practitioner or
21		pharmacist, the identity of and the type of
22		identification presented by] in a log book the full

<u>s</u>.b. NO. <u>967</u>

1		name, identification number, identification type, and
2		signature of the individual obtaining the controlled
3		substance. If the individual does not have any form
4		of proper identification, the pharmacist shall verify
5		the validity of the prescription and identity of the
6		patient with the prescriber, or their authorized
7		agent, before dispensing the controlled substance.
8		For the purpose of this section, "proper
9		identification" means government-issued identification
10		containing the photograph, printed name,
11		identification number, and signature of the individual
12		obtaining the controlled substance;
13	(7)	Who is a practitioner to predate or pre-sign
14		prescriptions to facilitate the obtaining or attempted
15		obtaining of controlled substances; or
16	(8)	Who is a practitioner to facilitate the issuance or
17		distribution of a written prescription or to issue an
18		oral prescription for a controlled substance when not
19		physically in the State."
20	SECT	ION 8. Section 329-52, Hawaii Revised Statutes, is
21	amended t	o read as follows:

<u>s</u>.B. NO. <u>967</u>

1	"§329-52 Administrative inspections [and warrants]. [-(a)-
2	Issuance and execution of administrative inspection warrants
3	shall be as follows:
4	(1) A judge of the circuit court, or any district judge
5	within the judge's jurisdiction, and upon proper oath
6	or affirmation showing probable cause, may issue
7	warrants for the purpose of conducting administrative
8	inspections authorized by this chapter or rules
9	hereunder, and seizures of the property appropriate to
10	the inspections. For purposes of the issuance of
11	administrative inspection warrants, probable cause
12	exists-upon showing a valid public-interest in the
13	effective enforcement of this chapter or rules
14	hereunder, sufficient to justify administrative
15	inspection of the area, premises, building or
16	conveyance in the circumstances specified in the
17	application for the warrant;
18	(2) A warrant shall issue only upon an affidavit of a
19	designated officer or employee having knowledge of the
20	facts-alleged, sworn to before the judge and
21	establishing the grounds for issuing the warrant. If
22	the judge is satisfied that grounds for the



1	application exist or that there is probable cause to
2	believe they exist, the judge shall issue a warrant
3	identifying the area, premises, building, or
4	conveyance to be inspected, the purpose of the
5	inspection, and, if appropriate, the type of property
6	to be inspected, if any. The warrant shall:
7	(A) State the grounds for its issuance and the name
8	of each person whose affidavit has been taken in
9	support thereof;
10	(B) Be directed to a person authorized by section
11	329-51 to execute it;
12	(C) Command the person to whom it is directed to
13	inspect the area, premises, building, or
14	conveyance identified for the purpose specified
15	and, if appropriate, direct the seizure of the
16	property specified;
17	(D) Identify the item or types of property to be
18	<pre>seized, if any;</pre>
19	(E) Direct that it be served during normal business
20	hours and designate the judge to whom it shall be
21	returned;

<u>S.B. NO.</u> 967

1	(3)	A-warrant issued pursuant to this section must be
2		executed and returned within ten days of its date
3		unless, upon a showing of a need for additional time,
4		the court orders otherwise. If property is seized
5		pursuant to a warrant, a copy shall be given to the
6		person from whom or from whose premises the property
7		is taken, together with a receipt for the property
8		taken. The return of the warrant shall be made
9		promptly, accompanied by a written inventory of any
10		property taken. The inventory shall be made in the
11		presence of the person executing the warrant and of
12		the person from whose possession or premises the
13		property was taken, if present, or in the presence of
14		at least one credible person other than the person
15		executing the warrant. A copy of the inventory shall
16		be delivered to the person from whom or from whose
17		premises the property was taken and to the applicant
18		for the warrant;
19	(4)	The judge who has issued a warrant shall attach
20		thereto a copy of the return and all papers returnable
21		in connection therewith and file them with the chief

<u>5.</u>B. NO. 967

1	clerk of the judicial circuit in which the inspection
2	was made.
3	(b) The department of public safety may make
4	administrative inspections of controlled premises in accordance
5	with the following provisions:
6	(1) For purposes of this section only, "controlled
~ 7	premises" means:
8	(A) Places where persons registered or exempted from
9	registration requirements under this chapter are
10	required to keep records; and
11	(B) Places including factories, warehouses,
12	establishments, and conveyances in which persons
13	registered or exempted from registration
14	requirements under this chapter are permitted to
15	hold, manufacture, compound, process, sell,
16	deliver, or otherwise dispose of any controlled
17	substance.
18	(2) When authorized by an administrative inspection
19	warrant issued pursuant to subsection (a) an officer
20	or employee designated by the department of public
21	safety, upon presenting the warrant and appropriate
22	credentials to the owner, operator, or agent in

<u>s</u>.b. NO. <u>967</u>

1		charge, may enter controlled premises for the purpose
2		of conducting an administrative inspection.
3	- (3) -	When authorized by an administrative inspection
4	N N	warrant, an officer or employee designated by the
5		department of public safety may:
6	~	(A) Inspect and copy records required by this chapter
7		to be kept;
8		(B) Inspect, within reasonable limits and in a
9		reasonable manner, controlled premises and all
10		pertinent equipment, finished and unfinished
11		material, containers and labeling found therein,
12		and, except as provided in subsection (b)(5), all
13		other things therein, including records, files,
14		papers, processes, controls, and facilities
15		bearing on violation of this chapter; and
16		(C) Inventory any stock of any controlled substance
17		therein and obtain samples thereof.
18	(4)	This section does not prevent the inspection without a
19		warrant of books and records pursuant to an
20		administrative subpoena issued in accordance with law,
21		nor does it prevent entries and administrative

Page 23

<u>s.b. no.</u> 967

1	inspections, including seizures of property, without a
2	warrant:
3	(A) If the owner, operator, or agent in charge of the
4	controlled premises consents;
5	(B) In situations presenting imminent danger-to
6	health or safety;
7	(C) In situations involving inspection of conveyances
8	if there is reasonable cause to believe that the
9	mobility of the conveyance makes it impracticable
10	to obtain a warrant;
11	(D) In any other exceptional or emergency
12	circumstance where time or opportunity to apply
13	for a warrant is lacking; or
14	(E) In all other situations in which a warrant is not
15	constitutionally required.
16	(5) An inspection authorized by this section shall not
17	extend to financial data, sales data, other than
18	shipment data, or pricing data unless the owner,
19	operator, or agent in charge of the controlled
20	premises consents in writing.]
21	(a) The administrator or any of the administrator's agents may
22	make administrative inspections of controlled premises upon

<u>S.B. NO.</u> 967

1	presentin	g appropriate credentials to the registrant or persons
2	subject t	o parts III, IV, VIII, and IX of this chapter or their
3	agents in	accordance with the following provisions:
4	(1)	Inspections shall be at reasonable times and within
5		reasonable limits and in a reasonable manner of
6		controlled premises and vehicles in which persons
7		registered or exempted from registration requirements
8		under this chapter are permitted to hold, manufacture,
9		compound, process, sell, dispense, deliver, or
10		otherwise dispose of any controlled substance or
11		regulated chemical designated under section 329-61 and
12		all pertinent equipment, finished and unfinished
13		materials, containers, and labeling therein to
14		determine if this chapter is being violated;
15	(2)	The administrator or any of the administrator's agents
16		shall have access to and may copy any and all records,
17		books, logs, or documents pertaining to the
18		administering, prescribing, dispensing, or sale of
19		controlled substances or regulated chemicals
20		designated under this chapter without a warrant; and
21	(3)	The administrator or any of the administrator's agents
22		may inventory any stock of any controlled substance or

<u>s</u>.b. NO. <u>967</u>

1		regulated chemical designated under section 329-61 and
2		secure samples or specimens of any drug, device, or
3		chemical not seized as evidence by paying or offering
4		to pay for the sample. The administrator shall make
5		or cause to be made examinations of samples secured
6		under this section to determine whether or not this
7		chapter is being violated.
8	(b)	An inspection of records authorized by this section
9	shall not	extend to financial data, data relating to pricing of
10	items, ot	her than shipment and sale amounts, unless the owner,
11	<u>operator,</u>	or agent in charge of the controlled premises consents
12	in writing	g.
12 13	<u>in writing</u> (c)	g. For purposes of this section, "controlled premises"
13	<u>(c)</u>	
13 14	(c) means:	For purposes of this section, "controlled premises"
13 14 15	(c) means:	For purposes of this section, "controlled premises" Places where persons registered or exempted from
13 14 15 16	(c) means:	For purposes of this section, "controlled premises" Places where persons registered or exempted from registration requirements under this chapter are
13 14 15 16 17	<u>(c)</u> <u>means:</u> <u>(1)</u>	For purposes of this section, "controlled premises" Places where persons registered or exempted from registration requirements under this chapter are required to keep records; and
13 14 15 16 17 18	<u>(c)</u> <u>means:</u> <u>(1)</u>	For purposes of this section, "controlled premises" Places where persons registered or exempted from registration requirements under this chapter are required to keep records; and Places, including factories, warehouses,
13 14 15 16 17 18 19	<u>(c)</u> <u>means:</u> <u>(1)</u>	For purposes of this section, "controlled premises" Places where persons registered or exempted from registration requirements under this chapter are required to keep records; and Places, including factories, warehouses, establishments, and conveyances in which persons

<u>s</u>.B. NO. **967**

1	otherwise dispose of any controlled substance or
2	regulated chemical designated under section 329-61."
3	SECTION 9. Statutory material to be repealed is bracketed
4	and stricken. New statutory material is underscored.
5	SECTION 10. This Act shall take effect upon its approval.
6	
7	INTRODUCED BY:
8	BY REQUEST

<u>S</u>.B. NO. 967

Report Title:

Controlled Substances

Description:

Makes Hawaii's controlled substance laws consistent with that of federal law and clarifies sections of chapter 329 relating to controlled substances.

SB 967

JUSTIFICATION SHEET

Public Safety

DEPARTMENT:

TITLE:

PURPOSE:

A BILL FOR AN ACT RELATING TO CONTROLLED SUBSTANCES.

Update chapter 329, Hawaii Revised Statutes, (HRS), to include amendments made to the federal Controlled Substance Act; clarify sections of chapter 329 relating to the issuance, revocation, and suspension of a registrants controlled substance registration; clarify sections of chapter 329, HRS, relating to the filling of controlled substances prescriptions; amend violations in prohibited acts B penalties; and amend the procedures for administrative inspections of registrants.

MEANS:

JUSTIFICATION:

Amend sections 329-16(b) and (e), 329-18(g), 329-33(a), 329-34(a), 329-38(c), 329-41(a), and 329-52, Hawaii Revised Statutes.

Proposed amendments to chapter 329, HRS, will accomplish the following:

- (1) Conform Hawaii's Controlled Substance Act (Chapter 329, HRS) with the federal Controlled Substance Act, Title 21, Chapter II, Part 1308.12(b)and(c), by adding the narcotic drugs Dihydroetorphine, Oripavine and Tincher of opium to Schedule II, as required by section 329-11(d), HRS.
- (2) Conform Hawaii's Controlled Substance Act (Chapter 329, HRS) with the federal Controlled Substance Act Title 21, Chapter II, Part 1308.12(d) by adding the stimulant drug Lisdexamfetamine to Schedule II, as required by section 329-11(d), HRS.
- (3) Conform Hawaii's Controlled Substance Act (Chapter 329, HRS) with the federal Controlled Substance Act Title 21, Chapter II, Part 1308.13(f) by adding the following list of Anabolic Steroids to Schedule III, as required by section 329-11(d), HRS:

3[beta], 17-dihydroxy-5a-androstane; 3[alpha], 17[beta]-dihydroxy-5aandrostane; 5[alpha]-androstan-3, 17-dione; 1-androstenediol (3[beta], 17[beta]dihydroxy-5[alpha]-androst-1-ene); 1-androstenediol (3[alpha], 17[beta]dihydroxy-5[alpha]-androst-1-ene); 4-androstenediol (3[beta], 17[beta]dihydroxy-androst-4-ene); 5-androstenediol (3[beta], 17[beta]dihydroxy-androst-5-ene); 1-androstenedione ([5[alpha]]-androst-1en-3, 17-dione); 4-androstenedione (androst-4-en-3, 17dione); 5-androstenedione (androst-5-en-3, 17dione); Bolasterone (7[alpha], 17[alpha]dimethy1-17[beta]-hydroxyandrost-4en-3-one); Calusterone (7[beta], 17[alpha]dimethyl-17[beta]-hydroxyandrost-4en-3-one); [Delta]1-dihydrotestosterone (a.k.a. `1testosterone') (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); Furazabol (17[alpha]-methyl-17[beta]hydroxyandrostano[2, 3-c]-furazan); 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; 4-hydroxytestosterone (4, 17[beta]dihydroxy-androst-4-en-3-one); 4-hydroxy-19-nortestosterone (4, 17[beta]-dihydroxy-estr-4-en-3-one); Mesterolone (1[alpha]methyl-17[beta]hydroxy-[5[alpha]]-androstan-3-one); Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1, 4-dien-3one); Methandriol (17[alpha]-methyl-3[beta], 17[beta]-dihydroxyandrost-5-ene); Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); 17[alpha]-methyl-3[beta], 17[beta]dihydroxy-5a-androstane; 17[alpha]-methyl-3[alpha], 17[beta]dihydroxy-5a-androstane; 17[alpha]-methyl-3[beta], 17[beta]dihydroxyandrost-4-ene;

	17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-
	hydroxyestr-4-en-3-one);
	Methyldienolone (17[alpha]-methyl- 17[beta]-hydroxyestra-4, 9(10)-dien-
	3-one;
	Methyltrienolone (17[alpha]-methyl-
	17[beta]-hydroxyestra-4, 9-11-trien-
	3-one;
	17[alpha]-methyl-[Delta]1-
	dihydrotestosterone (17b[beta]-
	hydroxy-17[alpha]-methyl-5[alpha]-
	androst-1-en-3-one) (a.k.a. '17-
	[alpha]-methyl-1-testosterone');
	19-nor-4-androstenediol (3[beta],
	17[beta]-dihydroxyestr-4-ene);
	19-nor-4-androstenediol (3[alpha],
	17[beta]-dihydroxyestr-4-ene);
	19-nor-5-androstenediol (3[beta],
	17[beta]-dihydroxyestr-5-ene);
	19-nor-5-androstenediol (3[alpha],
	17[beta]-dihydroxyestr-5-ene);
	19-nor-4-androstenedione (estr-4-en-
	3,17-dione);
	19-nor-5-androstenedione (estr-5-en-
	3,17-dione;
	Norbolethone (13[beta], 17[alpha]-
	diethyl-17[beta]-hydroxygon-4-en-3-
	one);
	Norclostebol (4-chloro-17[beta]-
	hydroxyestr-4-en-3-one);
	Normethandrolone (17[alpha]-methyl- 17[beta]-hydroxyestr-4-en-3-one);
	Stenbolone (17[beta]-hydroxy-2-methyl-
	[5[alpha]]-androst-1-en-3-one);
	Tetrahydrogestrinone (13[beta],
	17[alpha]-diethyl-17[beta]-
	hydroxygon-4, 9, 11-trien-3-one).
(4)	Clarify in sections 329-33 and 329-34
(=)	that if a practitioner during a DEA
	investigation surrenders the
	practitioner's Federal controlled
	substance registration then the
	practitioner's State registration shall
	be suspended.

(5) Amend section 329-38 relating to refills of schedule III through V controlled substance prescriptions. The amendment would allow retail pharmacies that electronically share the same real time, on line database to transfer up to the maximum number of refills. Section 329-38 is also amended to allow a pharmacy to transfer a refill for a controlled substance between islands.

- (6) Clarify the requirement for a pharmacy to verify the identity of the individual picking up the controlled substance by documenting, by signature on a logbook kept by the practitioner or pharmacist, recording the full name, type and adds the requirement of listing the identification number on the identification. This is necessary to better identify the person picking up the controlled substance.
- (7) Amend section 329-52, relating to administrative inspections and warrants, to conform to existing language in section 328-23, relating to inspections of registrants that administer, prescribe or dispense drugs.

Impact on the public: Protect the public by updating Hawaii's controlled substance schedules as well as assist pharmacist and physicians in better serving their patients by streamlining the requirements for dispensing controlled substances.

Impact on the department and other agencies: These proposed amendments would assist the Department's Narcotics Enforcement Division in clarifying regulations of the Uniform Controlled Substances Act.

GENERAL FUND:	None.
OTHER FUNDS:	None.
PPBS PROGRAM DESIGATION:	PSD 502.
OTHER AFFECTED AGENCIES:	Departmen Branch.

Department of Health, Food and Drug Branch.

EFFECTIVE DATE:

Upon approval.